Key result
Ticagrelor demonstrates superior efficacy compared with clopidogrel in ACS patients through novel interactions with the P2Y12 receptor and adenosine-mediated effects via ENT1 inhibition.
This editorial highlights novel pharmacological mechanisms of ticagrelor, including P2Y12 receptor interaction and ENT1 inhibition, which may explain its superior clinical efficacy over clopidogrel in acute coronary syndrome.
The superior efficacy of ticagrelor compared with clopidogrel in the management of patients with acute coronary syndrome (ACS), including a significant reduction in cardiovascular death, has led to a search for potential mechanisms for this superiority, such as in this issue of Blood in the work of Aungraheeta et al. They describe a novel property of ticagrelor in its interaction with the P2Y12 receptor as well as confirming adenosine-mediated effects through inhibition of cellular adenosine uptake via equilibrative nucleoside transporter 1 (ENT1).1
No takes yet. Share an insight, caveat, or question.
Parker et al. (2016) conducted an editorial in acute coronary syndrome (ACS). Ticagrelor vs. clopidogrel was evaluated. Ticagrelor demonstrates superior efficacy compared with clopidogrel in ACS patients through novel interactions with the P2Y12 receptor and adenosine-mediated effects via ENT1 inhibition.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: